# Genexa

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genexa

- Industry: Healthcare
- Headquarters: Atlanta, US
- Website: www.genexa.com
- Total disclosed funding: $60M
- Latest round: Series A (Jul 17, 2021)
- Investors on record: 5

## About

Genexa Inc. is a US-based company dedicated to creating clean over-the-counter medicines, emphasizing effective symptom relief without artificial ingredients, aiming to serve health-conscious families with safer alternatives for common ailments.Genexa Inc. specializes in the development and distribution of clean over-the-counter (OTC) medicines. The company is headquartered in Atlanta, US. Founded by Craig Williams, Genexa has secured USD 60 mn in SERIES A funding on July 17, 2021, led by Monogram Capital Partners, with participation from North Castle Partners, Point King Capital, Unilever Ventures, and Verlinvest. This round represents the total amount raised by the company, valuing it at USD 174.87 mn.Genexa specializes in the development and distribution of clean over-the-counter (OTC) medicines that prioritize effective symptom relief while eliminating artificial ingredients. Their core product line includes pain relief, cold and flu medications, digestive aids, sleep and stress solutions, allergy treatments, and homeopathic remedies, all formulated using the same active ingredients as leading pharmaceutical brands. Notably, Genexa replaces synthetic fillers with natural components such as organic agave syrup and organic flavors, ensuring that their offerings are free from artificial preservatives, sweeteners, and common allergens. The company primarily serves families and health-conscious consumers looking for safer medicine alternatives for their children and themselves, focusing on markets across the United States and select areas in Canada. By positioning itself as a leader in the clean medicine movement, Genexa aims to appeal to a growing demographic that seeks transparency and quality in healthcare products.Genexa generates revenue through direct sales to consumers and partnerships with retailers and wholesalers. The company’s products are available in various retail locations, allowing customers to purchase individual items or bundled packages. Revenue transactions typically involve consumers buying Genexa's flagship products, such as Kids' Pain & Fever and Kids' Allergy, through brick-and-mortar stores or online platforms. The pricing structure is designed to accommodate both individual purchases and multi-pack options, enhancing accessibility for families seeking clean medicine solutions. By maintaining a focus on community-oriented initiatives and product transparency, Genexa reinforces its market presence while fostering customer loyalty.In July 2021, Genexa Inc. raised USD 60 mn in SERIES A funding led by Monogram Capital Partners, intended to support its development efforts. The company is focused on expanding its product offerings and aims to introduce new clean OTC medications in the near future. Genexa plans to utilize the recent funding to enhance its product development initiatives, which include expanding into new markets, particularly targeting additional regions in Canada and possibly international markets by the end of the next fiscal year.

## Funding rounds

- Series A, Jul 17, 2021, $60M — North Castle Partners, Unilever Ventures, Verlinvest, Monogram Capital Partners, Point King Capital

## Investors

- North Castle Partners (https://capitalatlas.ai/funds/north-castle-partners) — Series A
- Unilever Ventures (https://capitalatlas.ai/funds/unilever-ventures) — Series A
- Verlinvest — Series A
- Monogram Capital Partners (https://capitalatlas.ai/funds/monogram-capital-partners) — Series A
- Point King Capital (https://capitalatlas.ai/funds/point-king-capital) — Series A